Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury
Jc. Yu et al., Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury, J PHARM EXP, 298(3), 2001, pp. 1172-1178
Citations number
40
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Exaggerated or inappropriate signaling by the platelet-derived growth facto
r receptor (PDGFR) tyrosine kinase has been implicated in a wide variety of
diseases. Thus, a series of piperazinyl quinazoline compounds were identif
ied as potent antagonists of the PDGFR by screening chemical libraries. An
optimized analog, CT52923, was shown to be an ATP-competitive inhibitor tha
t exhibited remarkable specificity when tested against other kinases, inclu
ding all members of the closely related PDGFR family. The PDGFRs and stem c
ell factor receptor were inhibited with an IC50 of 100 to 200 nM, while 45-
to >200-fold higher concentrations of CT52923 were required to inhibit fms
-like tyrosine kinase-3 and colony-stimulating factor-1 receptor, respectiv
ely. Other receptor tyrosine kinases, cytoplasmic tyrosine kinases, serine/
threonine kinases, or members of the mitogen-activated protein kinase pathw
ay were not significantly inhibited at 100- to 1000-fold higher concentrati
ons. In addition, this compound also demonstrated specificity for inhibitio
n of cellular responses. Platelet-derived growth factor-induced smooth musc
le cell migration or fibroblast proliferation was found to be blocked by CT
52923 with an IC50 of 64 and 280 nM, respectively, whereas 50- to 100-fold
higher concentrations were required to inhibit these responses when induced
with fibroblast growth factor. To investigate the effect of CT52923 on PDG
FR signaling, in vivo studies demonstrated that CT52923 could significantly
inhibit neointima formation following carotid artery injury by oral admini
stration in the rat. Therefore, PDGFR antagonism by CT52923 could be a viab
le strategy for the prevention of clinical restenosis or the treatment of o
ther human diseases involving PDGFR signaling.